Bibliography
- Sagare A , DeaneR, BellRDet al.: Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med. (2007) (Epub ahead of print).
- Blennow K , de LeonMJ, ZetterbergH: Alzheimer‘s disease. Lancet368(9533), 387–403 (2006).
- Andreasson U , PorteliusE, AnderssonME, BlennowK, ZetterbergH: Aspects of β-amyloid as a biomarker for Alzheimer‘s disease.Biomarkers Med.1(1), 59–78 (2007).
- Kanekiyo T , BanT, AritakeKet al.: Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid.Proc. Natl Acad. Sci. USA104(15), 6412–6417 (2007).
- Shibata M , YamadaS, KumarSRet al.: Clearance of Alzheimer‘s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier.J. Clin. Invest.106(12), 1489–1499 (2000).
- Hardy J , SelkoeDJ: The amyloid hypothesis of Alzheimer‘s disease: progress and problems on the road to therapeutics.Science297(5580), 353–356 (2002).
- Roberson ED , MuckeL: 100 years and counting: prospects for defeating Alzheimer‘s disease.Science314(5800), 781–784 (2006).
- Peskind ER , RiekseR, QuinnJF et al.: Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord.19(4), 220–225 (2005).
- Irizarry MC : Biomarkers of Alzheimer disease in plasma.NeuroRx1(2), 226–234 (2004).
- Kuo YM , EmmerlingMR, LampertHC et al.: High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer‘s disease. Biochem. Biophys. Res. Commun.257(3), 787–791 (1999).
- Selenica ML , WangX, Ostergaard-PedersenL, Westlind-DanielssonA, GrubbA: Cystatin C reduces the in vitro formation of soluble Aβ1–42 oligomers and protofibrils. Scand. J. Clin. Lab. Invest.67(2), 179–190 (2007).